See the latest news and media coverage for NeuroSense. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical-stage biotechnology company developing neurodegenerative disease therapies
neurosense-tx.comLast updated
In short: NeuroSense advanced its drug PrimeC for ALS, reporting a 65% reduction in death risk and planning a Health Canada filing for late 2026.
The redesigned clinical approach includes AI-driven formulation analysis, head-to-head trials against edaravone, and a streamlined Phase 3 pathway to reach regulators faster at lower cost.
Alon Ben-Noon details financing efforts for Phase 3 PrimeC study, Canadian regulatory submission plans, strategic discussions, and Nasdaq compliance measures.
Health Canada aligned on PrimeC ALS submission content and structure; standard review takes about 300 days.
The plasma biomarker analysis showed multiple distinctive protein changes, supporting PrimeC's target engagement and building on its previously reported safety profile.
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced a redesigned development plan...
2025 marked transition of PrimeC into a late-stage clinical asset with FDA-cleared Phase 3 program in ALS Statistically significant survival benefit demonstrated, including 65% reduction...
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced that it is targeting...
Detailed price information for Neurosense Therapeutics Ltd (NRSN-Q) from The Globe and Mail including charting and trades.
Track NeuroSense and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to NeuroSense and other trending companies.